Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
Autor: | Davies C; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. cathy.davies@kcl.ac.uk.; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. cathy.davies@kcl.ac.uk.; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. cathy.davies@kcl.ac.uk., Martins D; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychiatry, University Hospitals of Genève, Geneva, Switzerland., Dipasquale O; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., McCutcheon RA; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; Department of Psychiatry, University of Oxford, Oxford, UK., De Micheli A; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; Outreach And Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust, London, UK., Ramella-Cravaro V; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Provenzani U; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy., Rutigliano G; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Cappucciati M; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Oliver D; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; Department of Psychiatry, University of Oxford, Oxford, UK., Williams S; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Zelaya F; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Allen P; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Murguia S; Tower Hamlets Early Detection Service, East London NHS Foundation Trust, London, UK., Taylor D; Institute of Pharmaceutical Science, King's College London, London, UK., Shergill S; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; Kent and Medway Medical School, Canterbury, UK., Morrison P; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., McGuire P; Department of Psychiatry, University of Oxford, Oxford, UK.; NIHR Oxford Health Biomedical Research Centre, Oxford, UK.; Oxford Health NHS Foundation Trust, Oxford, UK., Paloyelis Y; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK., Fusar-Poli P; Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK.; Outreach And Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust, London, UK.; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. |
---|---|
Jazyk: | angličtina |
Zdroj: | Molecular psychiatry [Mol Psychiatry] 2024 May; Vol. 29 (5), pp. 1241-1252. Date of Electronic Publication: 2024 Jan 19. |
DOI: | 10.1038/s41380-024-02406-x |
Abstrakt: | Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical designs. Multi-echo resting-state fMRI data was acquired at approximately 1 h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all p (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |